InspireMD’s (NSPR) Overweight Rating Reaffirmed at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $4.50 price target on the stock.

Separately, StockNews.com initiated coverage on InspireMD in a research report on Sunday. They set a sell rating for the company.

InspireMD Stock Down 5.2 %

Shares of InspireMD stock opened at $2.55 on Tuesday. The stock has a market capitalization of $63.57 million, a price-to-earnings ratio of -3.36 and a beta of 0.90. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.85. The company has a 50-day simple moving average of $2.76 and a two-hundred day simple moving average of $2.51.

InspireMD (NYSE:NSPR) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The business had revenue of $1.74 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. On average, sell-side analysts anticipate that InspireMD will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Mesirow Financial Investment Management Inc. acquired a new stake in shares of InspireMD, Inc. (NYSE:NSPR) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned approximately 0.13% of InspireMD at the end of the most recent reporting period. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.